FDA approves Gilead’s new HIV drug Genvoya
SILVER SPRING, Md. — The Food and Drug Administration announced that it had approved Gilead Sciences’ Genvoya (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide, or E/C/F/TAF) to treat HIV. The drug, according to Gilead, is the first HIV treatment using a TAF-based regimen to get approval.
“Today’s approval of a fixed dose combination containing a new form of tenofovir provides another effective, once daily complete regimen for patients with HIV-1 infection,” said Dr. Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research.
The drug can be used in adults and children 12 years of age and older who haven’t taken an HIV therapy before, and HIV-positive adults whose virus is suppressed. The drug uses a new form of tenofovir that keeps the drug’s levels in the bloodstream low, but high in the cells where the disease replicates, in an effort to reduce side effects.
Camber rolls out new website
BY DSN STAFF
PISCATAWAY, N.J. — Camber Pharmaceuticals on Thursday unveiled its revamped website, featuring responsive design for optimal viewing on any device. The new website is also tailored to its user, with a product section that customizes results based on who is searching — patients, pharmacists or partners.
“Our new website is a reflection of our commitment to provide the very latest product information available and to offer the highest level of service to patients and customers alike,” Camber’s marketing director Kirk Hessels said. “The content management system for the site allows us to make updates the same day a product is launched giving our customers immediate access to product and bottle images, medication guides, SDS sheets, case dimensions and much more.”
Pfizer expands eligibility for RxPathways patient assistance programs
NEW YORK — Pfizer is looking to help more patients afford medication, announcing Thursday that it would be expanding eligibility for its RxPathways program, which offers services to help patients access medication. The change makes patients who earn up to four times the federal poverty level based on family size (up to $97,000 for a family of four) eligible for some of the 40 medicines offered for free by the program.
“We have listened to patients and acted quickly to significantly expand the eligibility of our patient assistance programs. While patient assistance is not a permanent solution, it is a necessary step for helping to solve some of the high co-pay issues that some patients face,” Pfizer’s EVP corporate affairs Sally Susman said. “The real solution is to have a system that provides patients with access to innovative new treatments their doctors’ prescribe and insurance plans with good coverage.”
Programs provided through Pfizer RxPathways include 35%-50% discounts on retail price of the company’s medicine for uninsured patients, medicine access counseling to help choose assistance programs, insurance counseling to understand coverage, co-pay cards and information on other co-pay assistance programs and referrals to other resources. Between 2010 and 2015, the company has assisted 2.5 million patients with the program.
Loading Post Please Wait...